Large-Scale Deletions of Mitochondrial DNA in Epilepsy Patients Treated with Carbamazepine
Main Article Content
Abstract
Mitochondrial dysfunction, caused by large-scale deletion mutations, can lead to impaired function of the mitochondrial respiratory chain, reduced ATP production, and serious effects on most energy-consuming organs, such as neurons, and can induce seizures in epilepsy. Carbamazepine (CBZ), the first-line drug used in the treatment of epilepsy, can be harmful to mitochondria and its side effects may be related to mitochondrial dysfunction. In this study, mitochondrial DNA (mtDNA) large-scale deletions were identified in 65 CBZ-treated patients with epilepsy, including 32 patients with CBZ-induced hypersensitivity and 33 with
CBZ tolerance. Using the PCR method, mtDNA large-scale deletions were identified in 21/65 epilepsy patients (32.31%), including 9/32 CBZ-hypersensitivity patients (28.13%) and 12/33 CBZ-tolerance patients (36.36%). However, this difference was not statistically significant. The “common deletion” of 4977 bp was the most prevalent deletion. Remarkably, the new deletion of 4876 bp in a CBZ-tolerance patient was reported for the first time. Quantitative PCR analysis showed that the level of mtDNA large-scale deletion was significantly lower in the hypersensitivity group than in the tolerance group (p < 0.05). Besides, analysis of the association between the level of mtDNA large-scale deletion and mtDNA copy number with the clinical features of CBZ hypersensitivity patients showed no relationship with age and severity of skin lesions (p > 0.05). However, there was a statistically significant association between the level of mtDNA large-scale deletions and sex (p < 0.01). Further studies are needed to evaluate the role of mtDNA large-scale deletions in epilepsy and their association with antiepileptic drugs.
References
[2] E. Beghi, G. Giussani, GBD 2016 Epilepsy Collaborators et al., Global, Regional, and National Burden of Epilepsy, 1990 - 2016: A Systematic Analysis for the Global Burden of Disease Study 2016, Lancet Neurol. Vol. 18,
No. 4, 2019, pp. 357-375.
[3] J. Gierbolini, M. Giarratano, S. R. Benbadis, Carbamazepine-Related Antiepileptic Drugs for the Treatment of Epilepsy - A Comparative Review, Expert Opin Pharmacother, Vol. 17, No. 7, 2016, pp. 885-888.
[4] J. Finsterer, S. Z. Mahjoub, Mitochondrial Toxicity of Antiepileptic Drugs and Their Tolerability in Mitochondrial Disorders, Expert Opin Drug Metab Toxicol, Vol. 8, 2012, pp. 71-79.
[5] I. Berger, I. Segal, D. Shmueli, A. Saada, The Effect of Antiepileptic Drugs on Mitochondrial Activity: A Pilot Study, J. Child Neurol, Vol. 25, No. 5, 2010, pp. 541-545.
[6] J. Folbergrová, W. S. Kunz, Mitochondrial Dysfunction in Epilepsy, Mitochondrion, Vol. 12, No.1, 2012, pp. 35-40.
[7] J. A. Dykens, Y. Will, The Significance of Mitochondrial Toxicity Testing in Drug Development, Drug Discov Today, Vol. 12, No. 17-18, 2007, pp. 777-785.
[8] S. Nadanaciva, Y. Will, Current Concepts in Drug-Induced Mitochondrial Toxicity, Curr Protoc Toxicol, Chapter 2: Unit 2.15, 2009, https://doi.org/10.1002/0471140856.tx0215s40.
[9] M. A. Dani, S. U. Dani, S. P. Lima, A. Martinez, B. M. Rossi, F. Soares, M. A. Zago, A. J. Simpson, Less DeltamtDNA4977 than Normal in Various Types of Tumors Suggests that Cancer Cells Are Essentially Free of this Mutation, Genet Mol Res, Vol. 3, No. 3, 2004, pp. 395-409.
[10] G. A. Cortopassi, D. Shibata, N. W. Soong, N. Arnheim, A Pattern of Accumulation of A Somatic Deletion of Mitochondrial DNA in Aging Human Tissues, Proc Natl Acad Sci U S A, Vol. 89, No. 16, 1992, pp. 7370-7374.
[11] R. Rossignol, B. Faustin, C. Rocher, M. Malgat, J. P. Mazat, T. Letellier, Mitochondrial Threshold Effects, J. Biochem, Vol. 370, No. Pt3, 2003, pp. 751-672.
[12] T. P. Bui, L. T. T. Nguyen, P. L. Le, N. T. T. Le, T. D. Nguyen, L. Van Nguyen, A. T. Van Nguyen, T. T. Trinh, Next-Generation Sequencing-Based HLA Typing Reveals the Association of HLA-B*46:01:01 and HLA-DRB1*09:01:02 Alleles with Carbamazepine-Induced Hypersensitivity Reactions in Vietnamese Patients with Epilepsy, Hum Immunol, Vol. 84, No. 3, 2023, pp. 186-195.
[13] J. Dimberg, T. T. Hong, M. Skarstedt, S. Löfgren, N. Zar, A. Matussek, Novel and Differential Accumulation of Mitochondrial DNA Deletions in Swedish and Vietnamese Patients with Colorectal Cancer, Anticancer Res, Vol. 34, No. 1, 2014, pp. 147-152.
[14] J. Dimberg, T. T. Hong, L. T. T. Nguyen, M. Skarstedt, S. Löfgren, A. Matussek, Common 4977 bp Deletion and Novel Alterations in Mitochondrial DNA in Vietnamese Patients with Breast Cancer, Springerplus, Vol. 4, 2015, pp. 58.
[15] L. He, P. F. Chinnery, S. E. Durham, E. L. Blakely, T. M. Wardell, G. M. Borthwick, R. W. Taylor, D. M. Turnbull, Detection and Quantification of Mitochondrial DNA Deletions in Individual Cells by Real-Time PCR, Nucleic Acids Res, Vol. 30, No. 14, 2002, pp. e68.
[16] L. Hu, X. Yao, Y. Shen, Altered Mitochondrial DNA Copy Number Contributes to Human Cancer Risk: Evidence from an Updated Meta-Analysis, Sci Rep, Vol. 6, 2016, pp. 35859.
[17] A. X. Fan, R. Radpour, M. M. Haghighi, C. Kohler, P. Xia, S. Hahn, W. Holzgreve, X. Y. Zhong, Mitochondrial DNA Content in Paired Normal and Cancerous Breast Tissue Samples from Patients with Breast Cancer, J. Cancer Res Clin Oncol, Vol. 135, No. 8, 2009, pp. 983-989.
[18] K. J. Krishnan, A. Bender, R. W. Taylor, D. M. Turnbull, A Multiplex Real-Time PCR Method to Detect and Quantify Mitochondrial DNA Deletions in Individual Cells, Anal Biochem, Vol. 370, No. 1, 2007, pp. 127-129.
[19] R. K. Bai, L. J. Wong, Simultaneous Detection and Quantification of Mitochondrial DNA Deletion(s), Depletion, and Over-Replication in Patients with Mitochondrial Disease, J. Mol Diagn, Vol. 7, No. 5 2005, pp. 613-622.
[20] G. Zsurka, W. S. Kunz, Mitochondrial Dysfunction and Seizures: The Neuronal Energy Crisis, Lancet Neurol, Vol. 14, No. 9, 2015, pp. 956-966.
[21] D. S. Khurana, I. Valencia, M. J. Goldenthal, A. Legido, Mitochondrial Dysfunction in Epilepsy, Seminars in Pediatric Neurology, Vol. 20, No. 3, 2013, pp. 176-187.
[22] D. Khurana, M. Goldenthal, I. Valencia, et al., Mitochondrial Respiratory Chain Dysfunction in Children with Epilepsy, Epilepsia, 2013.
[23] S. Waldbaum, M. Patel, Mitochondrial Dysfunction and Oxidative Stress: A Contributing Link to Acquired Epilepsy?, J. Bioenerg Biomembr, Vol. 42, 2010, pp. 449-455.
[24] S. J. Chang, B. C. Yu, Mitochondrial Matters of The Brain: Mitochondrial Dysfunction and Oxidative Status in Epilepsy, J. Bioenerg Biomembr, Vol. 42, 2010, pp. 457-459.
[25] B. Martinc, I. Grabnar, T. Vovk, The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress, Curr Neuropharmacol, Vol. 10, 2012, pp. 328-343.
[26] M. C. Debrinski, T. Horton, M. T. Lott, J. M. Shoffner, A. C. McKee, M. F. Beal, B. H. Graham, D. C. Wallace, Marked Changes in Mitochondrial DNA Deletion Levels in Alzheimer Brains, Genomics, Vol. 23, No. 2, 1994, pp. 471-476.
[27] G. Pagano, N. Ferrara, D. J. Brooks, N. Pavese, Age at Onset and Parkinson Disease Phenotype, Neurology, Vol. 86, No. 15, 2016, pp. 1400-1407.
[28] E. Volmering, P. Niehusmann, V. Peeva, A. Grote, G. Zsurka, J. Altmüller, P. Nürnberg, A. J. Becker, S. Schoch, C. E. Elger, W. S. Kunz, Neuropathological Signs of Inflammation Correlate with Mitochondrial DNA Deletions in Mesial Temporal Lobe Epilepsy, Acta Neuropathol, Vol. 132, No. 2, 2016, pp. 277-288.
[29] R. C. Vaught, D. K. Dowling, Maternal Inheritance of Mitochondria: Implications for Male Fertility?, Reproduction, Vol. 155, No. 4, 2018, pp. R159-R168.